We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Babcock International Group Plc | LSE:BAB | London | Ordinary Share | GB0009697037 | ORD 60P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-6.00 | -1.16% | 510.50 | 512.00 | 513.50 | 520.00 | 511.50 | 520.00 | 758,408 | 16:35:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Engineering Services | 4.44B | -35M | -0.0692 | -74.06 | 2.59B |
Date | Subject | Author | Discuss |
---|---|---|---|
13/11/2017 12:56 | 7 year lows | topdoc | |
13/11/2017 12:54 | Death cross on BAB | chutes01 | |
13/11/2017 11:40 | Perhaps shareholders should be emailing some Brexiteers (both Tory and Labour) to find out why, if there are massive opportunities outside the EU, the share prices of quite a few multinationals are very low at the moment. Clearly a majority of potential shareholders don't think so, otherwise the share prices would be rising. | yump | |
13/11/2017 10:19 | Results next week, no position atm. | essentialinvestor | |
13/11/2017 09:51 | Their may be a case for us now buying ULE, & hence our drop. | dogwalker | |
13/11/2017 09:45 | I am not totally convinced by that Ultra statement and I don't see why anyone should automatically read across. | minerve | |
13/11/2017 09:34 | Annoying, to say the least. | penycae | |
13/11/2017 08:51 | Ultra Electronics (ULE.L) down ~21% dragging others down too... | spypat | |
13/11/2017 08:38 | Someone know something we don’t? | utyinv | |
13/11/2017 08:33 | why is this tanking today | topdoc | |
09/11/2017 17:53 | Competitor Bristow sees things starting to improve for helicopters | smcni1968 | |
08/11/2017 14:16 | SMCNI1968 BAB Intrim Results Tuesday 21 November. | dave whitby | |
08/11/2017 14:09 | SMCNI1968 BAB Intrim Results Tuesday 21 November. | dave whitby | |
08/11/2017 14:09 | SMCNI1968 BAB Intrim Results Tuesday 21 November. | dave whitby | |
07/11/2017 21:34 | Good point Minerve. One of BAB's helicopter competitors (Bristow I think) announces results this week. | smcni1968 | |
02/11/2017 10:53 | Changing sentiment in the oil/energy sector with BP and RDSB updates this week is probably now turning its attention to here. | minerve | |
02/11/2017 10:30 | Interim results coming up late November | smcni1968 | |
02/11/2017 09:04 | Fingers crossed... It seems too cheap, but the experts must know better than me, or, just waiting in the wings for a bargain. I hope its not a case of having to wait until the next update for confidence to return, I fear it might. But how much lower can it go from here? I think the next support below where we are is circa 760, but that does seem far too low. | marsdenxjohn | |
02/11/2017 08:42 | Stating the obvious, but this really needs to find some support here. Added a few yesterday, as I thought the bottom was in. | penycae | |
01/11/2017 17:18 | Dave Whitby You have expressed my feelings entirely. It maybe that brokers are worried with the SNP Scottish dimension,or it could be that there is a deliberate attempt by the PROS to make it attractive for a take over proposal. Surely a foreign offer for BAB would be totally unacceptable. Is there a British firm who have the capability of combining with BAB as in S.Life/Aberdeen? Very perplexing! | rabbrooks | |
23/10/2017 08:58 | Vulgaris "Mind you, another IC columnist (Kate Beioley, p48) appears to think that a growing number of generic drug approvals is good for innovative biotechs and yet another (Megan Boxall) informs us, without apparent irony, that 'The NHS is the envy of many other countries'." They are right on both those points! An increase in generic drug approvals forces large pharmaceutical companies to replace lost revenue by targetting new areas of unmet need with drugs patent protected - the way they do this is by acquiring and having partnerships with innovative biotechs. As for the NHS, have you tried health services in other countries? You either have little available or you will need a seriously, seriously fat wallet. | minerve |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions